Epitranscriptomic Regulation of Inflammation in Ulcerative Colitis: Insights from METTL14, m6A, and the DHRS4-AS1/miR-206/A3AR Axis

Study Background and Research Question

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by persistent inflammation of the colon, with increasing global prevalence and significant patient morbidity. While genetic predisposition, immune dysregulation, and environmental factors are implicated, the molecular control of inflammatory responses in UC remains incompletely understood. Recent years have seen growing interest in the role of RNA modifications, particularly N6-methyladenosine (m6A), in regulating gene expression relevant to inflammatory processes and immune cell function. m6A is the most abundant internal modification on eukaryotic mRNAs and non-coding RNAs, installed by a methyltransferase complex including the METTL14 protein. The current reference study addresses the question: How does METTL14-mediated m6A methylation influence lncRNA-based regulatory networks and inflammatory signaling during UC progression?

Key Innovation from the Reference Study

The principal innovation of the study lies in delineating a mechanistic pathway where METTL14-driven m6A methylation of the long non-coding RNA DHRS4-AS1 enhances its stability and expression. This, in turn, regulates the miR-206/adenosine A3 receptor (A3AR) axis, ultimately modulating inflammatory injury in colonic epithelial cells. The research provides direct molecular evidence that METTL14 acts as a protective factor in UC by maintaining m6A levels on DHRS4-AS1 transcripts, positioning RNA methylation as a critical control point in the balance between inflammation and tissue homeostasis in the gut.

Methods and Experimental Design Insights

The study employs a combination of in vitro and in vivo models to dissect the role of METTL14 and m6A methylation in UC. Caco-2 human colonic epithelial cells were used to model inflammatory injury via TNF-α stimulation, with METTL14 knockdown achieved through siRNA transfection. Cell viability, apoptosis (via cleaved PARP and Caspase-3, and Bcl-2 levels), and inflammatory cytokine production were monitored. The activation of the NF-κB pathway—a key driver of inflammatory gene expression—was assessed post-METTL14 suppression.

To validate findings in vivo, a dextran sulfate sodium (DSS)-induced murine model of colitis was utilized, mirroring key features of human UC. METTL14 knockdown was performed in these mice, and colonic tissue was evaluated for histopathological damage and inflammation. Importantly, the study probed the epitranscriptomic landscape by quantifying m6A modification levels on DHRS4-AS1 and assessing the downstream regulatory relationships among DHRS4-AS1, miR-206, and A3AR using molecular and cellular assays.

Protocol Parameters

• Cell model: Caco-2 human colonic epithelial cells, exposed to 10 ng/mL TNF-α to induce inflammatory response.
• Gene knockdown: METTL14 silencing by siRNA transfection; validation by qRT-PCR and western blot.
• Apoptosis assays: Cleaved PARP and Caspase-3 (western blot); Bcl-2 quantification.
• Inflammatory pathway readouts: NF-κB activation (nuclear p65 translocation, target cytokines by ELISA or qPCR).
• In vivo model: C57BL/6 mice treated with 2.5% DSS in drinking water for 7 days to induce colitis; METTL14 knockdown via targeted delivery.
• lncRNA and miRNA modulation: DHRS4-AS1 overexpression or knockdown, and miR-206 mimic/inhibitor transfection, to dissect regulatory interactions.
• Histology: H&E staining for evaluation of tissue injury and inflammation in colonic sections.

Core Findings and Why They Matter

Results from the reference study show that METTL14 knockdown in Caco-2 cells leads to decreased cell viability, increased apoptosis, and elevated production of pro-inflammatory cytokines (including IL-1β, IL-6, TNF-α, and IFN-γ). Notably, METTL14 silencing activates the NF-κB pathway, a master regulator of inflammatory gene networks in UC. In vivo, METTL14 deficiency exacerbates DSS-induced colonic damage and inflammatory markers in mice, confirming its protective role.

At the molecular level, METTL14 depletion reduces m6A modification on DHRS4-AS1 transcripts, leading to their destabilization and decreased expression. DHRS4-AS1, in turn, was found to mitigate inflammatory injury by negatively regulating miR-206, which otherwise downregulates the adenosine A3 receptor (A3AR)—a receptor with known anti-inflammatory effects in the gut. Overexpressing DHRS4-AS1 was able to counteract the pro-inflammatory effects of METTL14 knockdown in vitro, supporting the existence of a critical METTL14/m6A—DHRS4-AS1—miR-206/A3AR axis in colonic inflammation.

These findings underscore the importance of m6A methylation in post-transcriptional gene regulation during immune responses and highlight how disruptions in RNA methylation machinery contribute to the pathogenesis of UC. This mechanistic insight has potential translational value, as targeting components of this axis could offer new therapeutic avenues for IBD.

Comparison with Existing Internal Articles

Several internal resources elaborate on the broader utility of methylation inhibition tools in dissecting epigenetic and inflammatory pathways. For example, 3-Deazaadenosine: Potent SAH Hydrolase Inhibitor for Meth... highlights the use of 3-Deazaadenosine as a validated S-adenosylhomocysteine hydrolase inhibitor, enabling precise suppression of SAM-dependent methyltransferase activity. This aligns with the reference paper’s emphasis on the pivotal role of methyltransferase complexes (including METTL14) in controlling m6A RNA modifications and, by extension, inflammatory gene expression.

Other articles, such as 3-Deazaadenosine: SAH Hydrolase Inhibitor for Methylation..., provide workflows for integrating S-adenosylhomocysteine hydrolase inhibitors into experimental models of methylation-dependent regulation in both inflammation and viral infection research. These resources collectively reinforce the translational relevance of manipulating methylation pathways—using both genetic and small-molecule approaches—for studying epigenetic regulation via methylation inhibition and preclinical antiviral research. However, while the internal articles focus on tool compounds and workflow guidance, the reference study uniquely dissects the endogenous interplay between m6A writers, lncRNAs, and miRNA-mediated signaling in a disease context.

Limitations and Transferability

While the study robustly demonstrates the METTL14—m6A—DHRS4-AS1—miR-206/A3AR axis in both cell culture and a mouse model of UC, certain limitations should be considered. The DSS model, while standard, does not fully recapitulate all aspects of human UC pathophysiology. Additionally, the regulatory relationships elucidated may be influenced by cell type or tissue microenvironment, raising questions of transferability to other forms of IBD or related inflammatory diseases. Furthermore, while the study implicates the axis in the context of colonic epithelial cells, broader roles in immune cell populations or systemic inflammation remain to be explored.

Why this cross-domain matters, maturity, and limitations

Bridging the study's findings with the use of S-adenosylhomocysteine hydrolase inhibitors, such as 3-Deazaadenosine, highlights an emerging experimental approach: chemical inhibition of methyltransferase activity to probe RNA methylation-dependent pathways in both inflammation and viral infection research. This cross-domain strategy is already supported in preclinical models, as outlined in internal resources, but its translation to therapeutic interventions in humans requires further validation and careful consideration of off-target effects and pathway specificity.

Research Support Resources

For research teams seeking to model or manipulate methylation-dependent regulatory mechanisms in inflammation or viral infection, small-molecule inhibitors are valuable complements to genetic approaches. 3-Deazaadenosine (SKU B6121) from APExBIO is a potent S-adenosylhomocysteine hydrolase inhibitor that elevates intracellular SAH levels, thereby suppressing SAM-dependent methyltransferase activities. Its application in preclinical workflows enables the study of epigenetic regulation via methylation inhibition and has demonstrated utility in both inflammatory and antiviral research models. Researchers interested in optimizing protocols for methylation pathway studies may find additional methodological guidance in internal articles on methylation research and preclinical antiviral workflows.